We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Read MoreHide Full Article
Key Takeaways
Indivior plans to merge with Supernus, creating a broader CNS company with 11 marketed medicines.
The combined company targets $125 million in annual cost synergies and $2.2 billion in revenues.
The deal could reduce Sublocade concentration while adding Supernus' CNS pipeline and research capabilities.
Indivior Pharmaceuticals (INDV - Free Report) agreed in August to combine with Supernus Pharmaceuticals (SUPN - Free Report) in an all-stock merger of equals. The deal would shift Indivior from a business centered on opioid use disorder into a broader central nervous system (CNS) company with 11 marketed medicines.
The transaction also offers scale, cost savings and added research capacity, but those benefits remain contingent on closing. Sublocade accounted for 69% of Indivior’s 2025 revenues, leaving the company heavily exposed to one product.
Indivior’s Merger Adds Scale Beyond Addiction
Indivior currently operates through a single segment focused on addiction treatments. Its 2025 net revenues were $1.2 billion, with Sublocade contributing $856 million and sublingual buprenorphine products generating $351 million.
Combining with Supernus would broaden that mix across psychiatry, neurology and addiction. The planned portfolio of 11 marketed medicines could reduce the concentration risk created by Sublocade, although the benefit will depend on performance after closing.
Indivior shareholders are expected to own approximately 56.5% of the combined company, while Supernus shareholders would hold 43.5%. Existing Indivior investors would therefore retain the majority ownership position.
Following completion, the company is expected to be headquartered at Supernus’ existing headquarters and continue trading on Nasdaq under the SUPN ticker. The combined organization is also expected to operate under the Supernus name.
Indivior Targets $125 Million in Annual Synergies
On a pro forma basis, the merged company is expected to generate approximately $2.2 billion in annual revenues and $888 million in adjusted EBITDA. Management also targets $125 million in annual cost synergies.
Those savings add a measurable financial rationale beyond diversification. Indivior raised its standalone 2026 adjusted EBITDA outlook to $700-$740 million after the second quarter, giving the proposed combination another cost-efficiency avenue alongside improving profitability.
Indivior Gains a Broader CNS Pipeline
Indivior’s internal pipeline has narrowed after it decided not to advance INDV-6001 into phase III and halted INDV-2000 following disappointing phase II data. The merger would add Supernus’ broader CNS research capabilities and pipeline programs while supporting additional business development.
Alkermes plc (ALKS - Free Report) provides relevant sector context. The neuroscience-focused company markets products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, showing how a CNS portfolio can extend across addiction, psychiatry and neurology.
Indivior Still Faces Merger Closing Conditions
The deal is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals and customary closing conditions. Until then, the projected diversification, synergies and pipeline expansion remain prospective.
Closing conditions matter because Indivior still depends heavily on Sublocade and faces ongoing litigation exposure related to opioids, antitrust claims and other matters. Those existing risks remain part of the investment case before the combination is completed.
Indivior’s Scores Frame the Deal From Strength
The proposed combination could give Indivior a broader product base, larger revenue scale and access to additional CNS pipeline programs. The central issue for 2026 is execution because the benefits are projected while closing conditions and product concentration remain unresolved.
Indivior currently carries a Zacks Rank #2 (Buy), a VGM Score of A and a Growth Score of A, along with a Value Score of B and Momentum Score of B. A top-two Zacks Rank paired with A- or B-level Style Scores is generally a favorable setup within the Zacks framework. The scores do not guarantee merger success, but they indicate supportive earnings-revision and style characteristics.
View the Zacks #1 Rank List
Image: Bigstock
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Key Takeaways
Indivior Pharmaceuticals (INDV - Free Report) agreed in August to combine with Supernus Pharmaceuticals (SUPN - Free Report) in an all-stock merger of equals. The deal would shift Indivior from a business centered on opioid use disorder into a broader central nervous system (CNS) company with 11 marketed medicines.
The transaction also offers scale, cost savings and added research capacity, but those benefits remain contingent on closing. Sublocade accounted for 69% of Indivior’s 2025 revenues, leaving the company heavily exposed to one product.
Indivior’s Merger Adds Scale Beyond Addiction
Indivior currently operates through a single segment focused on addiction treatments. Its 2025 net revenues were $1.2 billion, with Sublocade contributing $856 million and sublingual buprenorphine products generating $351 million.
Combining with Supernus would broaden that mix across psychiatry, neurology and addiction. The planned portfolio of 11 marketed medicines could reduce the concentration risk created by Sublocade, although the benefit will depend on performance after closing.
Indivior Pharmaceuticals Inc. Price and Consensus
Indivior Pharmaceuticals Inc. price-consensus-chart | Indivior Pharmaceuticals Inc. Quote
Indivior Shareholders Keep Majority Ownership
Indivior shareholders are expected to own approximately 56.5% of the combined company, while Supernus shareholders would hold 43.5%. Existing Indivior investors would therefore retain the majority ownership position.
Following completion, the company is expected to be headquartered at Supernus’ existing headquarters and continue trading on Nasdaq under the SUPN ticker. The combined organization is also expected to operate under the Supernus name.
Indivior Targets $125 Million in Annual Synergies
On a pro forma basis, the merged company is expected to generate approximately $2.2 billion in annual revenues and $888 million in adjusted EBITDA. Management also targets $125 million in annual cost synergies.
Those savings add a measurable financial rationale beyond diversification. Indivior raised its standalone 2026 adjusted EBITDA outlook to $700-$740 million after the second quarter, giving the proposed combination another cost-efficiency avenue alongside improving profitability.
Indivior Gains a Broader CNS Pipeline
Indivior’s internal pipeline has narrowed after it decided not to advance INDV-6001 into phase III and halted INDV-2000 following disappointing phase II data. The merger would add Supernus’ broader CNS research capabilities and pipeline programs while supporting additional business development.
Alkermes plc (ALKS - Free Report) provides relevant sector context. The neuroscience-focused company markets products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, showing how a CNS portfolio can extend across addiction, psychiatry and neurology.
Indivior Still Faces Merger Closing Conditions
The deal is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals and customary closing conditions. Until then, the projected diversification, synergies and pipeline expansion remain prospective.
Closing conditions matter because Indivior still depends heavily on Sublocade and faces ongoing litigation exposure related to opioids, antitrust claims and other matters. Those existing risks remain part of the investment case before the combination is completed.
Indivior’s Scores Frame the Deal From Strength
The proposed combination could give Indivior a broader product base, larger revenue scale and access to additional CNS pipeline programs. The central issue for 2026 is execution because the benefits are projected while closing conditions and product concentration remain unresolved.
Indivior currently carries a Zacks Rank #2 (Buy), a VGM Score of A and a Growth Score of A, along with a Value Score of B and Momentum Score of B. A top-two Zacks Rank paired with A- or B-level Style Scores is generally a favorable setup within the Zacks framework. The scores do not guarantee merger success, but they indicate supportive earnings-revision and style characteristics.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.